Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial / du Bois A., Minarik T. ... [et al.]. Onkológia Roč. 11, č. 1 (2016), s. 57-58